LuxuryCare Supports Groundbreaking Norovirus mRNA Vaccine Trial to Safeguard Residents and Staff
LuxuryCare, a leading care provider in Bournemouth and Poole, proudly celebrates a significant advancement in healthcare – the UK’s first-ever Norovirus mRNA vaccine trial, launched by the National Institute for Health Research (NIHR). This pioneering initiative promises to transform the way care homes manage the seasonal threat of Norovirus, a highly contagious virus often referred to as the “winter vomiting bug.”
A New Era in Norovirus Prevention
Norovirus outbreaks are a recurring challenge for care homes, posing serious health risks to elderly residents and impacting the well-being of dedicated care staff. The development of an mRNA vaccine represents a breakthrough in safeguarding vulnerable populations. By mitigating the risks associated with Norovirus, care homes like those operated by LuxuryCare can focus on delivering consistent, high-quality care without the disruptions caused by outbreaks.
Jacqueline Macon, Home Manager at Eagles Mount Care Home, shared her enthusiasm for the trial, stating:
“Norovirus outbreaks can disrupt not only the health of our residents but also the continuity of care and the wellbeing of our staff. We are delighted to support this trial and welcome opportunities to share our insights on Norovirus management within care environments. Our team is keen to contribute to this groundbreaking research and looks forward to seeing the positive impact on our residents and the wider care community.”
A Commitment to Innovation and Wellbeing
LuxuryCare’s involvement in this innovative research underscores their commitment to advancing healthcare measures that prioritise resident safety and wellbeing. By supporting the Norovirus mRNA vaccine trial, LuxuryCare is taking proactive steps to address seasonal health challenges and lead by example in the care sector.
Media Invitation
LuxuryCare extends a warm invitation to media representatives to visit Eagles Mount Care Home, where proactive measures against Norovirus are already in place. This is an opportunity to witness firsthand the dedication of staff and residents to enhancing health outcomes, as well as the vital role care homes play in supporting cutting-edge research.
